Immunoprecise Antibodies Ltd Quick Ratio (IPA) starting from the third quarter 2025 to third quarter 2024, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
Immunoprecise Antibodies Ltd   (NASDAQ: IPA)

Immunoprecise Antibodies Ltd 's Quick Ratio

IPA's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


In the wake of the increase in Current Liabilities in the third quarter 2025, Quick Ratio fell to 1.21 below Immunoprecise Antibodies Ltd average.

Within Major Pharmaceutical Preparations industry 378 other companies have achieved higher Quick Ratio than Immunoprecise Antibodies Ltd in third quarter 2025. While Quick Ratio total ranking in the third quarter 2025 has deteriorated compared to the prior quarter from 2191 to 3211.

Explain Quick Ratio?
How much Cash & cash equivalents IPA´s has?
What are IPA´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

IPA Quick Ratio (Jan 31 2026)
Q3		 (Oct 31 2025)
Q2		 (Jul 31 2025)
Q1		 (Apr 30 2025)
Q4		 (Jan 31 2025)
Q3
Y / Y Current Liabilities Change 4.89 % -58.38 % 48.99 % 4.89 % 37.23 %
Y / Y Cash & cash equivalent Change 166.93 % 329.6 % 303.72 % 166.93 % -54.21 %
Quick Ratio MRQ 1.21 3.23 1.05 1.21 0.48
IPA's Total Ranking # 3211 # 2191 # 3332 # 3469 # 2179
Seq. Current Liabilities Change 76.16 % -69.27 % 84.73 % 4.89 % -30.1 %
Seq. Cash & cash equivalent Change -33.91 % -5.23 % 59.67 % 166.93 % 6.36 %



Quick Ratio third quarter 2025 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 379
Healthcare Sector # 691
Overall Market # 2081


Quick Ratio Statistics
High Average Low
6.89 1.6 0.31
(Apr 30 2021)   (Oct 31 2024)




Financial Statements
Immunoprecise Antibodies Ltd 's Current Liabilities $ 7 Millions Visit IPA's Balance sheet
Immunoprecise Antibodies Ltd 's Cash & cash equivalent $ 8 Millions Visit IPA's Balance sheet
Source of IPA's Sales Visit IPA's Sales by Geography


Cumulative Immunoprecise Antibodies Ltd 's Quick Ratio

IPA's Quick Ratio for the trailling 12 Months

IPA Quick Ratio

 (Jan 31 2026)
12 Months		 (Oct 31 2025)
12 Months		 (Jul 31 2025)
12 Months		 (Apr 30 2025)
12 Months		 (Jan 31 2025)
12 Months
Y / Y Current Liabilities TTM Growth -2.12 % 2.74 % 34.45 % 28.19 % 36.84 %
Y / Y Cash & cash equivalent TTM Growth 241.35 % 131.1 % 69.32 % 9.29 % -37.25 %
Quick Ratio TTM 1.4 1.25 0.78 0.57 0.4
Total Ranking TTM # 2065 # 2191 # 3332 # 3469 # 1218
Seq. Current Liabilities TTM Growth 1.07 % -15.42 % 13.33 % 1.03 % 6.08 %
Seq. Cash & cash equivalent TTM Growth 13.95 % 34.93 % 56.6 % 41.78 % -22.86 %

Quick ratio ranking by company, industry and sector >> Back to IPA Financial Strength Comparisons >> Go to Compare IPA Quick Ratio to its Competitors

On the trailing twelve months basis IPA Cash & cash equivalent more than doubled by 166.93 % in Q3 2025 year on year, faster than Current Liabilities, this led to increase in in Immunoprecise Antibodies Ltd 's Quick Ratio to 1.4, Quick Ratio remained below IPA average.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 492 other companies have achieved higher Quick Ratio than Immunoprecise Antibodies Ltd . While Quick Ratio total ranking has deteriorated compared to the previous twelve months ending in the second quarter 2025 from to 0.

Explain Quick Ratio?
How much Cash & cash equivalents IPA´s has?
What are IPA´s Current Liabilities?

TTM Quick Ratio Company Ranking
Within: No.
Within the Major Pharmaceutical Preparations Industry # 493
Healthcare Sector # 1014
Within the Market # 3211


trailing twelve months Quick Ratio Statistics
High Average Low
3.24 1.57 0.43
(Apr 30 2022)   (Apr 30 2024)




Companies with similar Quick Ratio in the quarter ending Jan 31 2026, within Major Pharmaceutical Preparations Industry Quick RatioJan 31 2026 MRQ Cash & cash equivalentJan 31 2026 MRQ Current Liabilities
Urogen Pharma Ltd   3.32 $ 160.074  Millions$ 48.225  Millions
Decoy Therapeutics Inc   3.29 $ 13.710  Millions$ 4.166  Millions
Bolt Biotherapeutics Inc   3.26 $ 27.505  Millions$ 8.435  Millions
Bullfrog Ai Holdings Inc   3.25 $ 2.184  Millions$ 0.672  Millions
Madrigal Pharmaceuticals Inc   3.18 $ 983.559  Millions$ 309.270  Millions
Aclaris Therapeutics Inc   3.17 $ 90.751  Millions$ 28.645  Millions
Pyxis Oncology Inc   3.16 $ 66.857  Millions$ 21.131  Millions
Skye Bioscience Inc   3.14 $ 25.737  Millions$ 8.206  Millions
Acurx Pharmaceuticals inc   3.12 $ 7.556  Millions$ 2.421  Millions
Gri Bio Inc   3.11 $ 8.229  Millions$ 2.643  Millions
Cypherpunk Technologies Inc   3.11 $ 14.035  Millions$ 4.520  Millions
Inhibitor Therapeutics Inc   3.10 $ 2.375  Millions$ 0.766  Millions
Kyntra Bio Inc   3.04 $ 88.978  Millions$ 29.242  Millions
Tao Synergies Inc   3.03 $ 5.498  Millions$ 1.814  Millions
Kala Bio inc   3.03 $ 7.557  Millions$ 2.494  Millions
Lb Pharmaceuticals Inc  3.01 $ 30.466  Millions$ 10.126  Millions
Ardelyx inc   2.99 $ 264.689  Millions$ 88.605  Millions
Kiniksa Pharmaceuticals International Plc  2.98 $ 414.074  Millions$ 139.184  Millions
Gt Biopharma Inc   2.95 $ 6.811  Millions$ 2.308  Millions
Cytomx Therapeutics Inc   2.94 $ 137.052  Millions$ 46.615  Millions
Mirum Pharmaceuticals Inc   2.89 $ 732.452  Millions$ 253.075  Millions
Nurix Therapeutics Inc   2.86 $ 246.960  Millions$ 86.471  Millions
Proqr Therapeutics N v   2.85 $ 103.503  Millions$ 36.334  Millions
Cellectar Biosciences Inc   2.84 $ 13.196  Millions$ 4.650  Millions
Verastem Inc   2.84 $ 204.990  Millions$ 72.268  Millions
Pds Biotechnology Corp  2.83 $ 26.712  Millions$ 9.447  Millions
Tvardi Therapeutics Inc   2.82 $ 30.811  Millions$ 10.926  Millions
Nasus Pharma Ltd   2.82 $ 4.286  Millions$ 1.520  Millions
Can fite Biopharma Ltd   2.82 $ 8.540  Millions$ 3.029  Millions
Connect Biopharma Holdings Limited  2.82 $ 38.348  Millions$ 13.613  Millions

Date modified: 2026-09-18T17:05:50+00:00



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.